Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth
J Gotlib - Blood, The Journal of the American Society of …, 2022 - ashpublications.org
Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …
neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can …
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …
Polycythemia vera: current pharmacotherapy and future directions
B Hensley, H Geyer, R Mesa - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: In the past, management of polycythemia vera (PV) was built upon a
cornerstone of control over erythrocytosis, through therapeutic phlebotomy, as well as the …
cornerstone of control over erythrocytosis, through therapeutic phlebotomy, as well as the …
Recent advances in the treatment of polycythemia vera
A Duek, M Berla, MH Ellis - Leukemia & Lymphoma, 2022 - Taylor & Francis
Polycythemia vera (PV) has long been recognized as a disease characterized by excess
blood cell production leading to thromboembolic phenomena. While the focus of treatment is …
blood cell production leading to thromboembolic phenomena. While the focus of treatment is …
How I treat polycythemia vera
AM Vannucchi - Blood, The Journal of the American Society of …, 2014 - ashpublications.org
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with JAK2
mutations (V617F or exon 12) in almost all cases. The World Health Organization has …
mutations (V617F or exon 12) in almost all cases. The World Health Organization has …
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal
expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or …
expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or …
[HTML][HTML] Therapy of polycythemia vera: is it time to change?
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) driven by JAK2 mutations in
most cases.[1] The disease has an increased risk of thromboembolic complications and a …
most cases.[1] The disease has an increased risk of thromboembolic complications and a …
[HTML][HTML] Advances in the treatment of polycythemia vera: trends in disease management
Abstract Treatment modalities for polycythemia vera (PV) have evolved over time.
Phlebotomy and low-dose aspirin suffice in low-risk patients, but cytoreductive therapies are …
Phlebotomy and low-dose aspirin suffice in low-risk patients, but cytoreductive therapies are …
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a
substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A …
substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A …
[HTML][HTML] Polycythemia vera treatment algorithm 2018
Recently reported mature survival data have confirmed the favorable prognosis in
polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger …
polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger …